Over two years ago, on May 18, 2018, Hyphens Pharma International made its Catalist debut on the Singapore Exchange at 30 cents. In the subsequent 18 months, its share price barely moved a needle, leading CFO Fang Lee Wei to say the counter was “under-recognised and severely undervalued”.

“Even though retail investors may have been using our products, not many of them know our brand since Hyphens focuses mainly on business-to-business distribution,” she tells The Edge Singapore in a recent interview. 

Things have been changing course for the pharmaceutical distributor which has been bringing the Hyphens brand to retail investors through roadshows, events and social media engagements. These have helped push the counter to gain some 8.5 cents or 28.8% to close at 38.5 cents on Sept 10. More recently, its share price has been on the uptrend, with a notable surge on July 15 when it finished at 48 cents, some 50% or 16 cents higher than the previous day’s 32-cent close. In the process, some 55.8 million shares changed hands.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook